PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-200.00%
Both yoy net incomes decline, with VET at -339.56%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
9.09%
D&A growth well above VET's 15.21%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-200.00%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
533.33%
SBC growth while VET is negative at -44.50%. John Neff would see competitor possibly controlling share issuance more tightly.
-1225.00%
Both reduce yoy usage, with VET at -327.87%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
-7000.00%
AR is negative yoy while VET is 0.00%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
700.00%
Some yoy usage while VET is negative at -327.88%. John Neff would see competitor possibly generating more free cash from minor accounts than we do.
211.11%
Lower 'other non-cash' growth vs. VET's 654.41%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
24.67%
Some CFO growth while VET is negative at -12.74%. John Neff would note a short-term liquidity lead over the competitor.
-17.13%
Negative yoy CapEx while VET is 25.55%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
170.59%
Some acquisitions while VET is negative at -2.19%. John Neff sees competitor possibly pausing M&A or divesting while the firm invests in new deals.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
520.00%
We have some outflow growth while VET is negative at -195.03%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
13.95%
Investing outflow well above VET's 4.02%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
-4.55%
Both yoy lines negative, with VET at -21.91%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
No Data
No Data available this quarter, please select a different quarter.
19.82%
Buyback growth of 19.82% while VET is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.